Valiant Organics Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹304 Cr +93.6% YoYSee revenue, profit and what management said. You are viewing Q1 FY25.
VO

Valiant Organics Ltd

Q1 FY25Chemicals & Petrochemicals

Valiant Organics Q1 FY25 earnings call: Revenue & Margins

Q1 FY25 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹168Cr
−5.1% QoQ
Net profit
−₹1Cr
Margin
9%
+10.2 pp QoQ

Based on Valiant Organics Ltd's Q1 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹411
Market cap₹1.2K Cr
P/E23.7

The short version

Q1-FY25 Revenue from Operations: INR 1,679 Mn - Year-on-Year Revenue Change: - Standalone: Decreased 4.9% from INR 1,766 Mn in Q1-FY24 (Page 13) - Consolidated: Decreased 16.8% from INR 2,018 Mn in Q1-FY24 (Page 12) - Sales Volumes (MT) by Key Chemistries (Q1-FY25 vs Q1-FY24): - Chlorination: 660 MT vs 697 MT - Hydrogenation: 543 MT vs 475 MT - Ammonolysis: 118 MT vs 127 MT - Others: 333 MT vs 271 MT (Page 11) - Explicit Outlook: - Demand in dyes and pigments industry has improved with optimism for agrochemicals and pharmaceuticals sectors to increase demand soon. Q1-FY25 Consolidated EBITDA: INR 157 Mn, down 34.3% YoY (from INR 239 Mn in Q1-FY24) - Q1-FY25 Consolidated EBITDA Margin: 9.35%, down 249 bps YoY (from 11.84% in Q1-FY24) - Q1-FY25 Consolidated P

From Valiant Organics Ltd's Q1 FY25 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q1-FY25 Revenue from Operations: INR 1,679 Mn
  • Year-on-Year Revenue Change:
  • Standalone: Decreased 4.9% from INR 1,766 Mn in Q1-FY24 (Page 13)
  • Consolidated: Decreased 16.8% from INR 2,018 Mn in Q1-FY24 (Page 12)
  • Sales Volumes (MT) by Key Chemistries (Q1-FY25 vs Q1-FY24):
  • Chlorination: 660 MT vs 697 MT
  • Hydrogenation: 543 MT vs 475 MT
  • Ammonolysis: 118 MT vs 127 MT
  • Others: 333 MT vs 271 MT (Page 11)
  • Explicit Outlook:

2 more points from Valiant Organics Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Valiant Organics Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

See what Valiant Organics Ltd said on capital expenditure plans — free account, 30 seconds.

Top-ranked in Chemicals & Petrochemicals

Ranked on what management guided this quarter

Guidance-ranked
2Shiv Texchem
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Valiant Organics Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Valiant Organics Ltd said on order book & pipeline — free account, 30 seconds.

Valiant Organics Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Valiant Organics Ltd Q1 FY25 results — key figures

Valiant Organics Ltd Q1 FY25 reported results vs year-ago quarter, ₹ crore
₹ CrQ1 FY25Q4 FY24QoQ
Revenue168177-5.1%
Operating profit (EBITDA)16-2—
Operating margin9%-1.2%+10.2 pp
Profit before tax2-25—
Net profit (PAT)-1-20—
EPS (₹)-0.22-7.32—

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹304 Cr, net profit ₹17 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Chemicals & Petrochemicals this season

  • Himadri Special (Q1 FY25)

    1,199.77 Cr, up 26.17% YoY (vs Rs. Key concall takeaways from Himadri Speciality Chemical Ltd's Q1 FY25 earnings call — and how it ranks against sector peers.

  • Balaji Amines (Q1 FY25)

    Q1FY25 consolidated revenue from operations: ₹393 crore, down 16% YoY from ₹469 crore in Q1FY24 (Page 5 & 6). Key concall takeaways from Balaji Amines Ltd's Q1…

  • Linde India (Q1 FY25)

    Revenue for year ended Mar 2024: ₹27,687 million, down 12% vs. Key concall takeaways from Linde India Ltd's Q1 FY25 earnings call — and how it ranks against…

  • Vidhi Specialty (Q1 FY25)

    83.0 Crs, up 4.1% year-on-year from Rs. Key concall takeaways from Vidhi Specialty Food Ingredients Ltd's Q1 FY25 earnings call — and how it ranks against…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Valiant Organics Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Valiant Organics Ltd Q1 FY25 results?

Q1-FY25 Revenue from Operations: INR 1,679 Mn - Year-on-Year Revenue Change: - Standalone: Decreased 4.9% from INR 1,766 Mn in Q1-FY24 (Page 13) - Consolidated: Decreased 16.8% from INR 2,018 Mn in Q1-FY24 (Page 12) - Sales Volumes (MT) by Key Chemistries (Q1-FY25 vs Q1-FY24): - Chlorination: 660 MT vs 697 MT - Hydrogenation: 543 MT vs 475 MT - Ammonolysis: 118 MT vs 127 MT - Others: 333 MT vs 271 MT (Page 11) - Explicit Outlook: - Demand in dyes and pigments industry has improved with optimism for agrochemicals and pharmaceuticals sectors to increase demand soon. Q1-FY25 Consolidated EBITDA: INR 157 Mn, down 34.3% YoY (from INR 239 Mn in Q1-FY24) - Q1-FY25 Consolidated EBITDA Margin: 9.35%, down 249 bps YoY (from 11.84% in Q1-FY24) - Q1-FY25 Consolidated P

What is Valiant Organics Ltd share price analysis?

Valiant Organics Ltd currently shows a neutral. The stock trades at a P/E of 23.7 with a market cap of ₹1,196 Cr. Investors should review the full earnings analysis for detailed insights.

Keep Valiant Organics Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.